BusinessOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer PatientsBy Nasdaq OMXJan 4, 2017, 1:32 PM UTC
BusinessCompanion Diagnostics Market worth 5.58 Billion USD by 2019; Transparency Market ResearchBy Nasdaq OMXSep 27, 2016, 12:04 PM UTC